索菲亚基因组学
SOPH
6.73
-0.56
-7.68%
索菲亚基因组学
US · SOPH
#3618 按市值排名
上市于 2021
6.73
-0.56
-7.68%
实时 - 追踪5344个代码 - 心跳于555秒前
· 2026-10-16 19:54
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 62.01% +0.02pp
- 机构数量
- 80
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund30.23%
VC/PE Fund18.59%
Hedge Fund9.93%
Individual/Insider8.51%
Private Company3.12%
Public Company0.11%
Other29.48%
主要股东 截至 2026-02-15
Alychlo NV
8.22% · 6.99M 股
Generation Investment Management LLP
7.98% · 6.79M 股
aMoon Ventures Y.SH. Ltd
6.47% · 5.51M 股
Aigh Capital Management, LLC
4.65% · 3.95M 股
Akre Capital Management, LLC
4.37% · 3.72M 股
Jurgi Camblong
4.04% · 3.44M 股
Royce & Associates, LP
3.97% · 3.38M 股
Balderton Capital (UK) LLP
3.88% · 3.30M 股
Principal Global Investors, LLC
2.78% · 2.36M 股
Columbia Management Investment Advisers, LLC
2.60% · 2.22M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 0次买入 · 50次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Jurgi Camblong | Chief Executive Officer | 4.04% |
| Ross Muken | Chief Financial Officer | 0.79% |
| Zhenyu Xu | Chief Scientific Officer | 0.65% |
| Vincent Ossipow | Independent Non-Executive Director | 0.59% |
| Daan van Well | Executive VP, Chief Legal Officer & General Counsel | 0.40% |
| Troy Cox | Independent Non-Executive Chairperson | 0.36% |
| George Cardoza | Chief Financial Officer | 0.36% |
| Didier Hirsch | Independent Non-Executive Director | 0.26% |
| Philippe Menu | Executive VP, Chief Medical Officer & Chief Product Officer | 0.24% |
| Jean-Michel Yves Cossery | Director | 0.22% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-04 | George Cardoza | Chief Financial Officer | Intent to Sell (Form 144) | -1,592 | $8.07 |
| 2026-10-04 | Jurgi Camblong | Chief Executive Officer | Intent to Sell (Form 144) | -65,672 | $8.07 |
| 2026-10-04 | Zhenyu Xu | Chief Scientific Officer | Intent to Sell (Form 144) | -19,394 | $8.07 |
| 2026-10-04 | Manuela Da Valente | Chief Human Resources Officer | Intent to Sell (Form 144) | -4,240 | $8.07 |
| 2026-10-04 | Philippe Menu | Executive VP, Chief Medical Officer & Chief Product Officer | Intent to Sell (Form 144) | -22,394 | $8.07 |
| 2026-09-20 | Ross Muken | Chief Financial Officer | Automatic Disposition | -422 | $8.33 |
| 2026-09-20 | George Cardoza | Chief Financial Officer | Automatic Disposition | -774 | $8.33 |
| 2026-09-13 | Zhenyu Xu | Chief Scientific Officer | Automatic Disposition | -4,000 | $7.88 |
| 2026-09-13 | Philippe Menu | Executive VP, Chief Medical Officer & Chief Product Officer | Automatic Disposition | -5,000 | $7.88 |
| 2026-09-10 | Daan van Well | Executive VP, Chief Legal Officer & General Counsel | Automatic Disposition | -6,168 | $7.63 |
| 2026-09-09 | Jurgi Camblong | Chief Executive Officer | Automatic Disposition | -8,500 | $7.66 |
| 2026-09-07 | Kathy Hibbs | Independent Non-Executive Director | Automatic Disposition | -6,250 | $8.13 |
| 2026-08-26 | Zhenyu Xu | Chief Scientific Officer | Automatic Disposition | -10,000 | $8.91 |
| 2026-08-24 | Kathy Hibbs | Independent Non-Executive Director | Automatic Disposition | -6,250 | $8.68 |
| 2026-08-24 | Philippe Menu | Executive VP, Chief Medical Officer & Chief Product Officer | Automatic Disposition | -5,000 | $8.68 |
| 2026-08-23 | Abhimanyu Verma | Chief Technology Officer | Automatic Disposition | -10,000 | $8.20–8.80 |
| 2026-08-20 | Zhenyu Xu | Chief Scientific Officer | Automatic Disposition | -20,000 | $7.94–8.41 |
| 2026-08-19 | Zhenyu Xu | Chief Scientific Officer | Intent to Sell (Form 144) | -6,000 | $8.28 |
| 2026-08-18 | Zhenyu Xu | Chief Scientific Officer | Intent to Sell (Form 144) | -8,000 | $7.62 |
| 2026-08-18 | Manuela Da Valente | Chief Human Resources Officer | Derivative Exercise and Sale | -10,000 | $3.20–7.94 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:54:25 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
索菲亚基因组学 讨论区 0 条评论